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Abstract
Aims The aim of this study was to evaluate the safety profile in terms of changes in renal function after co‐treatment with
sacubitril/valsartan and empagliflozin in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction
(HFrEF).
Methods and results This multicentre observational analysis included 108 patients with T2D and HFrEF treated with both
agents: baseline sacubitril/valsartan (Group A; n = 43), baseline empagliflozin (Group B; n = 42), or both agents initiated simul-
taneously (Group C; n = 23). The primary endpoint was estimated glomerular filtration rate (eGFR) dynamics across treatment
groups. A binary characterization of worsening renal function (WRF)/improved renal function (IRF) was included in the primary
endpoint. WRF and IRF were defined as an increase/decrease in serum creatinine ≥ 0.3 mg/dL or GFR ≥ 20%. Changes in quan-
titative variables were evaluated using joint modelling of survival and longitudinal data (JM). Rates and their treatment differ-
ences were determined by Poisson regression. The mean left ventricle ejection fraction and eGFR were 32 ± 6% and
70 ± 28 mL/min/1.73 m2, respectively. At a median follow‐up of 1.01 years (inter‐quartile range 0.71–1.50), 377 outpatient
visits were recorded. Although there were differences in GFR trajectories over time within each treatment, they did not
achieve statistical significance (omnibus P = 0.154). However, when these differences were contrasted among groups, there
was a significant decrease in GFR in Group A as compared with Group B (P = 0.002). The contrast between Groups C and B
was not significant (P = 0.430). These differences were also reflected when the rates for WRF and IRF were contrasted among
treatments.
Conclusions The co‐administration of sacubitril/valsartan and empagliflozin in patients with HFrEF and concomitant T2D ap-
pears to be safe in terms of renal function.
Keywords Heart failure with reduced ejection fraction (HFrEF); Type 2 diabetes mellitus; Sacubitril/valsartan; SGLT2i; Renal func-
tion; Renal safety profile
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Introduction
The angiotensin receptor neprilysin inhibitor (ARNI)
sacubitril/valsartan has become fundamental in the treatment
of heart failure (HF) with reduced ejection fraction (HFrEF).1
Sodium‐glucose co‐transporter‐2 inhibitors (SGLT2is) have
also shown promise in patients with HFrEF with and without
type 2 diabetes (T2D).2 Sacubitril/valsartan and SGLT2is result
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in a superior renal function profile at long‐term follow‐up
as compared with enalapril and placebo, respectively.3–6
However, both treatments may cause short‐term renal
dysfunction.5,7
Renal function after concomitant administration of
sacubitril/valsartan and SGLT2i in patients with HFrEF and
T2D is currently uncertain. Here, we evaluated renal
function dynamics during concomitant treatment with
sacubitril/valsartan and empagliflozin in addition to contem-
porary treatment in a cohort of consecutive ambulatory
patients with HFrEF and T2D.
Methods
Study design and patients
This is a consecutive multicentre observational study of
108 patients with chronic HFrEF and T2D who received
empagliflozin and sacubitril/valsartan in addition to standard
treatment. Only patients receiving sacubitril/valsartan and
empagliflozin, according to the European Medicines Agency
approved indication and current guidelines, were included
in this analysis. All patients were treated with renin–
angiotensin system (RAS) inhibitors before starting
sacubitril/valsartan. Patients were included from 1 March
2017 to 1 December 2018, from four dedicated HF clinics
at tertiary hospitals in Spain. The timing for initiation, combi-
nation, and up‐titration of these two drugs was left to
the discretion of the patient’s physician by following
established recommendations. At the baseline visit, 43 pa-
tients were already being treated with sacubitril/valsartan
and empagliflozin (Group A), 42 were already being treated
with empagliflozin and sacubitril/valsartan (Group B), and
23 patients were prescribed both drugs simultaneously
(Group C). All patients were treated with both empagliflozin
and sacubitril/valsartan after the baseline visit.
Clinical monitoring
Ambulatory follow‐up was performed in the HF units of
each centre. At each clinical visit (baseline and follow‐up),
we recorded demographic information, medical history
[New York Heart Association (NYHA) class], vital signs (systolic
blood pressures and heart rate), 12‐lead electrocardiogram
results, standard laboratory data, and concomitant changes
in HF therapy. Standard laboratory data included serum
creatinine, estimated glomerular filtration rate (eGFR) as
determined by CKD‐EPI, haemoglobin, sodium, and potas-
sium at all visits.
Endpoints
The primary endpoint of the study was the safety profile
in terms of changes in renal function as represented by
the eGFR after co‐treatment with sacubitril/valsartan and
empagliflozin. A binary characterization of worsening renal
function (WRF)/improved renal function (IRF) was included
in the primary endpoint. WRF was defined as an increased se-
rum creatinine ≥ 0.3 mg/dL or decreased GFR ≥ 20%. IRF was
defined as a decrease in creatinine ≥ 0.3 or an increase in
GFR ≥ 20%. A sensitivity analysis evaluating the trajectory
of creatinine clearance (Cockcroft–Gault formula) were also
analysed.
Statistical analysis
Continuous variables were expressed as means (±1 SD) or
medians [inter‐quartile range (IQR)] and discrete variables
as percentages. Comparisons of means, medians, and fre-
quencies among treatment groups were carried out with
one‐way ANOVA, Kruskal–Wallis test, and χ2, respectively.
Because the treatment groups of interest were assembled
after the baseline visit, most of the analyses included the data
beginning at the first follow‐up visit; data on variables mea-
sured at baseline were used as covariates in the regression
models. Changes in quantitative variables were evaluated
using linear mixed regression, with random slopes on partici-
pant ID, random coefficient on continuous follow‐up time,
and unstructured covariance. These models included as
fixed effects the interaction of treatment group with time
(modelled as 4 df RCS), the baseline value of the longitudinal
outcome tested, and the following baseline variables
(age, eGFR, length of prior exposure to each treatment,
left ventricular ejection fraction, serum sodium, and
treatment with beta‐blockers and aldosterone receptor
blockers). In addition, furosemide‐equivalent dose (FED) and
sacubitril/valsartan and empagliflozin doses were added as
time‐specific covariates (time varying). For binary WRF/IRF,
incidence rates and the treatment ratio were estimated by
Poisson regression analysis. Stata 15.1 (Stata Statistical Soft-
ware, Release 15 [2017]; StataCorp LP, College Station, TX,
USA) was used for the analyses.
Results
The mean age of the total cohort at baseline was
69 ± 9 years (range 73–80 years); 75% of patients were male,
63.9% had ischaemic heart disease, 58.7% had a history of a
previous admission for acute HF, and 71.3% of patients were
NYHA II. The mean left ventricular ejection fraction, eGFR,
creatinine, BUN, and systolic blood pressure was 32 ± 6%,
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70 ± 28mL/min/1.73m2, 1.18 ± 0.42mg/dL, 26.5 ± 13mg/dL,
and 128 ± 21 mmHg, respectively. The median NT‐proBNP
was 1795 pg/mL (IQR 715–4234). At baseline, most of the pa-
tients were receiving loop diuretics (80.6%), beta‐blockers
(96.3%), and mineralocorticoid receptor antagonists (79.6%).
Detailed baseline characteristics for all patients are presented
in Table 1. No significant differences were found across treat-
ment groups. The time on treatment (length of exposure)
with sacubitril/valsartan (Group A) and empagliflozin (Group
B) was 133 (60–253) and 100 days (47–210), respectively.
Treatment titration during follow‐up and adverse
events
This study included 120.8 person‐years of follow‐up or a total
of 382 patient‐visits. At a median follow‐up of 1.01 years (IQR
0.71–1.50), there was a median of three visits per patient
(range 2–15). After baseline, the first, second, and third visits
occurred at a median of 38.5 (IQR 23–119), 143 (IQR 68–232),
and 245 days (IQR 146–313), respectively.
Sacubitril/valsartan was up‐titrated in 27 patients during
the follow‐up. After up‐titration, the follow‐up visit oc-
curred at a median of 66 (IQR 30–163) days. The propor-
tion of patients taking medium (100 mg b.i.d.) and
higher doses (200 mg b.i.d.) of sacubitril/valsartan in-
creased during follow‐up (P = 0.001) without differences
among groups (P = 0.112; Figure S1). No differences
were found for doses of empagliflozin during the
follow‐up in the whole sample (mean dose = 10 mg q.d.;
P = 0.379) and across treatment groups (interaction P‐
value = 0.896).
During follow‐up, WRF occurred in six (22.2%) patients in
whom sacubitril/valsartan was up‐titrated and in 26 (32.1%)
in whom it was not (P = 0.330). No patient experienced an
eGFR decrease ≥50%, development of end‐stage renal dis-
ease, or death due to renal failure.
Sacubitril/valsartan was down‐titrated in three (2.8%) pa-
tients. The reason for down‐titration was symptomatic hypo-
tension in two (1.8%) patients and WRF in one patient (0.9%).
However, the drug was not withdrawn in any of these
patients.
Table 1 Baseline characteristics across treatment groups




first (n = 43) Total (n = 108) P‐value
Age, years 69 ± 10 70 ± 9 68 ± 9 69 ± 9 0.599
Male sex, n (%) 18 (78.3) 30 (71.4) 33 (76.7) 81 (75.0) 0.784
Clinical features of heart failure
Ischaemic aetiology, n (%) 14 (60.9) 26 (61.9) 29 (67.4) 69 (63.9) 0.820
Left ventricular ejection fraction, % 31 ± 6 32 ± 6 32 ± 6 32 ± 6 0.887
NT‐proBNP, pg/mL* 2145 (1483; 4609) 2117 (662; 4731) 1600 (628; 3136) 1795 (715; 4234) 0.283
CA125, U/mL* 44 (14; 114) 38 (14; 92) 44 (21; 66) 42 (15; 84) 0.875
NYHA functional class, n (%) 0.699
I 0 (0.0) 2 (4.8) 3 (7.0) 5 (4.6)
II 16 (69.6) 30 (71.4) 31 (72.1) 77 (71.3)
III 7 (30.4) 9 (21.4) 9 (20.9) 25 (23.1)
IV 0 (0.0) 1 (2.4) 0 (0.0) 1 (0.9)
Heart rate, mmHg, 68 ± 10 73 ± 15 76 ± 14 73 ± 14 0.102
Systolic blood pressure, mmHg 127 ± 23 128 ± 22 129 ± 18 128 ± 21 0.946
Creatinine, mg/dL 1.25 ± 0.51 1.18 ± 0.39 1.13 ± 0.39 1.18 ± 0.42 0.540
Estimated GFR, mL/min/1.73 m2 64.4 ± 20.6 68.3 ± 27.9 74.1 ± 31.0 69.8 ± 27.9 0.374
Medical history, n (%)
Hypertension 21 (91.3) 33 (78.6) 36 (83.7) 90 (83.3) 0.418
Ischaemic heart disease 14 (60.9) 25 (59.5) 30 (69.8) 69 (63.9) 0.582
Atrial fibrillation 8 (34.8) 17 (40.5) 16 (37.2) 41 (38.0) 0.895
Prior admission for AHF, n (%) 13 (56.5) 17 (40.5) 14 (32.6) 44 (40.7) 0.168
Background therapy, n (%)
Mineralocorticoid receptor
antagonist
18 (78.3) 33 (78.6) 35 (81.4) 86 (79.6) 0.933
Beta‐blocker 22 (95.7) 42 (100.0) 40 (93.0) 104 (96.3) 0.231
Ivabradine 9 (39.1) 12 (28.6) 7 (16.3) 28 (25.9) 0.115
Implantable cardioverter‐defibrillator 3 (13.0) 7 (16.7) 12 (27.9) 22 (20.4) 0.270
Cardiac resynchronization therapy 2 (8.7) 5 (11.9) 3 (7.0) 10 (9.3) 0.732
Loop diuretics 20 (87.0) 37 (88.1) 30 (69.8) 87 (80.6) 0.070
Thiazides 2 (8.7) 3 (7.1) 5 (11.6) 10 (9.3) 0.771
Metformin 19 (82.6) 22 (52.4) 31 (72.1) 72 (66.7) 0.029
GFR was estimated using the Modification of Diet in Renal Disease Study (MDRD) formula. Continuous variables are expressed as
mean ± standard deviation, unless otherwise specified.
AHF, acute heart failure; CA125, antigen carbohydrate 125; GFR, glomerular filtration rate; NT‐proBNP, amino‐terminal pro‐brain natri-
uretic peptide; NYHA, New York Heart Association.
*Values expressed as median (inter‐quartile range).
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Sacubitril/valsartan was withdrawn in one patient owing to
symptomatic hypotension. Empagliflozin was stopped in
seven patients, mainly owing to urinary/genital tract infection
(n = 4). In the other three cases treated with empagliflozin,
the reason for withdrawal was not recorded.
When modelled over time, the FED decreased in all groups
(mainly during the first 6 months), without significant differ-
ential effect across treatment groups (Figure S2). Neither
loop diuretics nor thiazides were prescribed in 21 patients
at follow‐up. In 22 patients (20.4%), loop diuretic doses were
down‐titrated at least once (12.8%, 21.7%, and 30.4% for
Groups A, B, and C, respectively; P = 0.239).
During the entire follow‐up, six deaths (5.6%), nine (8.3%)
admissions for acute HF, and seven visits to the emergency
room (6.5%) were recorded. No differences were found
among the treatment groups (Table S1).
Changes in renal function
Overall trajectory by treatment group
The slope of the GFR trajectories for Groups A and B
showed a bimodal response with an early increase (first
6 months) and a later plateau or decrease. The slope for
the Group B trajectory was statistically significant different
from 0 (flat slope). Group C, on the other hand, showed
a consistent increase over the entire follow‐up (Figure 1).
Analysis of differences between groups (using Group B as
a reference) over the continuum of the follow‐up showed
a significant decrease in eGFR for Group A (Figure 2A).
The overall trajectory comparing Group B vs. C showed
no significant differences (Figure 2B). Similar trajectories
among treatments groups were found when creatinine
clearance was evaluated (Figure S3). Likewise, we did not
find significant changes in blood urea nitrogen and serum
sodium Figures S4 and S5).
Worsening and improved renal function
During the entire follow‐up, 45 and 38 episodes of
WRF and IRF were recorded in 33 (30.6%) and 23 (21.3%)
patients, respectively. Mean crude rates for WRF and
IRF are presented in Figure 3A and B, respectively.
Overall, patients belonging to Group A had the highest
rates of WRF1. Conversely, Group B had the lowest and
Figure 1 Continuous changes in eGFR across treatment groups. Group A: patients on stable sacubitril/valsartan treatment in which empagliflozin was
initiated. Group B: patients on stable empagliflozin treatment in which sacubitril/valsartan was initiated. Group C: naïve patients in which sacubitril/
valsartan and empagliflozin were initiated simultaneously. eGFR, glomerular filtration rate (mL/min/1.73 m2). eGFR was determined by CKD‐EPI
formula.
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highest rates for WRF and IRF, respectively. Intermediate
rates were found in Group C. No patients met the WRF2
criteria.
Compared with Group B, and assuming a constant effect
over the follow‐up, patients in the Group A showed a signifi-
cant increase in the risk of WRF1 (IRR = 2.36, 95% CI: 1.03–
Figure 2 Changes in renal function compared between groups. Group A: patients on stable sacubitril/valsartan treatment in which empagliflozin was
initiated. Group B: patients on stable empagliflozin treatment in which sacubitril/valsartan was initiated. Group C: naïve patients in which sacubitril/
valsartan and empagliflozin were initiated simultaneously. Group B was used as a reference.
Figure 3 Renal function trajectories across treatment groups. (A) Worsening renal function (WRF) rate. (B) Improved renal function (IRF) rate. Group
A: patients on stable sacubitril/valsartan treatment in which empagliflozin was initiated. Group B: patients on stable empagliflozin treatment in which
sacubitril/valsartan was initiated. Group C: naïve patients in which sacubitril/valsartan and empagliflozin were initiated simultaneously.
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5.43; P = 0.043). No significant differences were found for
Group C (IRR = 2.02, 95% CI: 0.88–4.67; P = 0.097). Likewise,
and compared with Group B, patients belonging to Group A
showed a lower risk of IRF (IRR = 0.20, 95% CI: 0.05–0.83;
P = 0.027) without differences for Group C (IRR = 0.86, 95%
CI: 0.32–2.28; P = 0.767).
Discussion
In this observational multicentre registry, we found that
co‐administration of sacubitril/valsartan and empagliflozin in
patients with chronic HFrEF, T2D, and normal or mildly re-
duced renal function (eGFR > 60 mL/min/1.73 m2) did not
translate into significant and clinically relevant changes in
eGFR. None of the patients in this cohort had a >50% de-
crease in eGFR during the follow‐up. When examined contin-
uously using smaller changes in renal function parameters
(increase/decrease in creatinine ≥ 0.3 or decrease/increase
in GFR ≥ 20%), we found that the higher risk of WRF was at-
tributable to empagliflozin initiation in those already being
treated with sacubitril/valsartan. Conversely, initiation of
sacubitril/valsartan in those already being treated with
empagliflozin was associated with IRF. An intermediate risk
of WRF was found when both treatments were initiated
simultaneously.
These findings suggest that the combined ARNI‐SGLT2
inhibition appears to have a similar renal safety profile (at
mid‐term) as previously reported when both treatments are
used separately.3,4,6,8 Our results are somehow reassuring
considering that these two treatments seem to have inde-
pendent and additive benefits when used in combination.
Notably, the present findings do not apply to other HF sce-
narios (e.g. patients with more than mild renal dysfunction,
no T2D, and acute HF syndromes) in which we should likely
be more conservative and vigilant.
Combined administration of empagliflozin and
sacubitril/valsartan: friend or foe for the kidney
Given the observational nature of this study, we can
only speculate how empagliflozin and sacubitril/valsartan
exerted their effects on kidney function (Figure 4). Both
Figure 4 Hypothesized renal haemodynamic effects of co‐administration of SGLT2i and sacubitril/valsartan in patients with HFrEF and T2D. Group A:
patients on stable sacubitril/valsartan treatment in which empagliflozin was initiated. SGLT2i causes pre‐glomerular vasoconstriction via TGF activation
with a coinciding drop in intra‐glomerular pressures. A post‐glomerular vasodilatation effect via adenosine A2 receptor activation has also been sug-
gested. Group B: patients on stable empagliflozin treatment in which sacubitril/valsartan was initiated. NPs decrease pre‐glomerular vascular resistance
and may counteract the vasoconstrictive action of SGLT2 inhibition on the pre‐glomerular arteriole. Group C: naïve patients in which sacubitril/
valsartan and empagliflozin were initiated simultaneously. An intermediate effect on afferent arteriole tone could be expected by the concomitant ad-
ministration of both treatments. A1R, adenosine type 1 receptor; A2R, adenosine type 1 receptor; ARBs, angiotensin receptor blockers; FF, filtration
fraction; GFR, glomerular filtration rate; IRF, improved renal function; NPs, natriuretic peptides; RBF, renal blood flow; TGF, tubuloglomerular feedback;
WRF, worsening renal function.
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SGLT2 and neprilysin receptors are abundantly expressed in
the kidneys.
Several explanations are possible for the early slight
decrease in eGFR after empagliflozin initiation in patients
already being treated with ARNI. First, it may be related to
an adenosine‐mediated increase in afferent pre‐glomerular
arteriolar resistance with a coinciding decrease in
intra‐glomerular pressure.9,10 Second, recent findings suggest
a predominant vasodilatory effect of SGLT2is on efferent ar-
terioles mediated by adenosine A2 receptor activation when
the potential for pre‐glomerular vasoconstriction has already
been achieved.11 The authors observed that eGFR was ac-
companied by stable, or even reduced, pre‐glomerular vascu-
lar resistance, suggesting that post‐glomerular vasodilation
explains the acute decrease in eGFR after SGLT2i initiation.11
Third, in addition to the aforementioned glomerular haemo-
dynamic effects, a reduction in proximal tubular sodium reab-
sorption together with enhanced tubular flow secondary to
osmotic diuresis may increase substrate availability in the dis-
tal nephron.12,13 Accordingly, SGLT2is may work synergisti-
cally with more distal diuretics, potentiating diuresis and
natriuresis.14 This aspect is relevant, as 80% of patients were
receiving loop diuretics at baseline. An alternative explana-
tion could be related to plasma volume contraction rather
than ‘true’ WRF15,16; we observed FED reductions in all
groups, mainly during the first 6 months of follow‐up.
In contrast, eGFR slightly improved when
sacubitril/valsartan was added to patients who were already
treated with empagliflozin. Natriuretic peptides (NPs) are
known to reduce pre‐glomerular vascular resistance and
may also increase the filtration surface area by relaxing glo-
merular mesangial cells.17 However, the renal effects of these
peptides are markedly attenuated in HF because renal
neprilysin activity and protein expression levels are upregu-
lated in this syndrome.18 Accordingly, neprilysin inhibition
by sacubitril/valsartan may boost the effects of NPs on
glomerular haemodynamic. The immediate increase in uri-
nary albumin/creatinine ratio observed in PARADIGM‐HF af-
ter initiation of sacubitril/valsartan, with normalization to
pre‐screening values following discontinuation, clearly sug-
gests a haemodynamic effect.3 Therefore, the observed im-
provement in eGFR in our cohort after the introduction of
sacubitril/valsartan suggests that it may counteract the vaso-
constrictive action of empagliflozin on the pre‐glomerular ar-
teriole. In addition, sacubitril/valsartan promptly reduces
cardiac filling pressures and promotes left ventricular reverse
remodelling,7,19 which may also have contributed to en-
hanced renal blood flow.
Limitations
As an observational study, causality cannot be inferred. Addi-
tional limitations of this study are the limited sample size,
which is prone to bias because of unmeasured confounding,
and eGFR may not be the most accurate and sensitive
parameter for detecting early renal function changes16,20
Additionally, the cohort was primarily composed of ambula-
tory patients with chronic HFrEF, concomitant T2D, and
normal or mildly reduced renal function. Therefore, it is
unclear how the results will apply to the broader HF popula-
tion, those without T2D, and patients with higher degrees
of renal impairment. Finally, we did not measure other surro-
gates of renal haemodynamic and urine parameters that
may be useful to explain these results. Therefore, all the
conclusions are merely speculative and only allow us to
generate hypothesis about the underlying mechanism behind
these findings.
Conclusions
The co‐administration of sacubitril/valsartan and
empagliflozin in ambulatory patients with chronic HFrEF,
T2D, and normal or mildly reduced renal function appears
to be safe in terms of renal function. A better renal function
profile emerged when sacubitril/valsartan was added to
empagliflozin. Further studies are needed to unravel the
potential synergistic effect of both treatments in terms of
cardiorenal outcomes.
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Figure S1. Sacubitril valsartan dose pattern at follow‐up.
Group A: patients on stable sacubitril/valsartan treatment in
which empagliflozin was initiated. Group B: patients on stable
empagliflozin treatment in which sacubitril/valsartan was ini-
tiated. Group C: naïve patients in which sacubitril/valsartan
and empagliflozin were initiated simultaneously.
Figure S2. Furosemide‐equivalent dose pattern during the first
6‐months in the whole sample (A), without significant differenetial
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effect acroos teratment groups (B). Group A: patients on stable
sacubitril/valsartan treatment in which empagliflozin was initiated.
Group B: patients on stable empagliflozin treatment in which
sacubitril/valsartan was initiated. Group C: naïve patients in which
sacubitril/valsartan and empagliflozin were initiated simultaneously.
Table S1. Adverse events across treatment groups
Figure S3. Predicted Cockroft‐Gault formula trajectories. Group A: pa-
tients on stable sacubitril/valsartan treatment in which empagliflozin
was initiated. Group B: patients on stable empagliflozin treatment in
which sacubitril/valsartan was initiated. Group C: naïve patients in
which sacubitril/valsartan and empagliflozin were initiated
simultaneously.
Figure S4. Continuous changes in BUN across treatment groups. Group
A: patients on stable sacubitril/valsartan treatment in which
empagliflozin was initiated. Group B: patients on stable empagliflozin
treatment in which sacubitril/valsartan was initiated. Group C: naïve
patients in which sacubitril/valsartan and empagliflozin were initiated
simultaneously. BUN, blood urea nitrogen
Figure S5. Continuous changes in serum sodium across treatment
groups. Group A: patients on stable sacubitril/valsartan treatment in
which empagliflozin was initiated. Group B: patients on stable
empagliflozin treatment in which sacubitril/valsartan was initiated.
Group C: naïve patients in which sacubitril/valsartan and empagliflozin
were initiated simultaneously.
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